Med BioGene Inc
Many Bright Ideas Technologies Inc. does not have significant operations. Previously, the company was involved in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. Many Bright Ideas Technologies Inc. is headquartered in Vancouver, Canad… Read more
Med BioGene Inc (MBGNF) - Total Assets
Latest total assets as of September 2025: $5.78K USD
Based on the latest financial reports, Med BioGene Inc (MBGNF) holds total assets worth $5.78K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Med BioGene Inc - Total Assets Trend (2004–2024)
This chart illustrates how Med BioGene Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Med BioGene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Med BioGene Inc's total assets of $5.78K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.3% |
| Accounts Receivable | $605.00 | 17.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Med BioGene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Med BioGene Inc's current assets represent 100.0% of total assets in 2024, an increase from 80.9% in 2004.
- Cash Position: Cash and equivalents constituted 25.3% of total assets in 2024, down from 46.1% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 17.4% of total assets.
Med BioGene Inc Competitors by Total Assets
Key competitors of Med BioGene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Med BioGene Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Med BioGene Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Med BioGene Inc is currently not profitable relative to its asset base.
Med BioGene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.05 | 0.46 |
| Quick Ratio | 0.03 | 0.05 | 0.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-211.92K | $ -165.45K | $ -96.34K |
Med BioGene Inc - Advanced Valuation Insights
This section examines the relationship between Med BioGene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 27.10 |
| Asset Growth Rate (YoY) | 50.5% |
| Total Assets | $3.48K |
| Market Capitalization | $94.32K USD |
Valuation Analysis
Premium Asset Valuation: The market values Med BioGene Inc's assets at a significant premium ( 27.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Med BioGene Inc's assets grew by 50.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Med BioGene Inc (2004–2024)
The table below shows the annual total assets of Med BioGene Inc from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.48K | +50.52% |
| 2023-12-31 | $2.31K | -22.83% |
| 2022-12-31 | $3.00K | -72.23% |
| 2021-12-31 | $10.79K | -86.81% |
| 2020-12-31 | $81.83K | +522.16% |
| 2019-12-31 | $13.15K | +279.57% |
| 2018-12-31 | $3.46K | +151.82% |
| 2017-12-31 | $1.38K | -97.04% |
| 2016-12-31 | $46.46K | +75.27% |
| 2015-12-31 | $26.51K | -82.42% |
| 2014-12-31 | $150.80K | -17.98% |
| 2013-12-31 | $183.85K | -56.33% |
| 2012-12-31 | $421.04K | -55.18% |
| 2011-12-31 | $939.44K | +325.81% |
| 2010-12-31 | $220.62K | -89.83% |
| 2009-12-31 | $2.17 Million | +85.68% |
| 2008-12-31 | $1.17 Million | -43.36% |
| 2007-12-31 | $2.06 Million | +170.64% |
| 2006-12-31 | $762.56K | +367.40% |
| 2005-12-31 | $163.15K | +11.44% |
| 2004-12-31 | $146.40K | -- |